IND – Page 13 – Pharma.Tips

Reproducibility issues in screening data during portfolio review – decision framework regulators expect

Addressing Reproducibility Issues in Screening Data During Portfolio Evaluations In the pharmaceutical sector, inconsistent screening data can hinder the transition of promising compounds through the drug development pipeline, impacting decision-making…

Off-target toxicity signals during early discovery – risk mitigation strategy

Identifying and Mitigating Off-Target Toxicity Signals in Early Drug Discovery In the realm of pharmaceutical research, the early stages of drug discovery play a pivotal role in assessing the potential…

Poor hit-to-lead progression before IND-enabling studies – how to avoid late-stage attrition

“`html Understanding and Addressing Poor Hit-to-Lead Progression Before IND-Enabling Studies Poor hit-to-lead progression can derail drug discovery efforts and significantly delay the initiation of Investigational New Drug (IND)-enabling studies. In…

Off-target toxicity signals during translational assessment – risk mitigation strategy

Mitigating Risks of Off-Target Toxicity Signals During Translational Assessment In the complex landscape of pharmaceutical development, detecting off-target toxicity signals during translational assessment poses a significant risk to the success…

Lead candidate fails downstream criteria before IND-enabling studies – decision framework regulators expect

“`html Evaluating the Failure of a Lead Candidate in Downstream Criteria Prior to IND-Enabling Studies In the complex world of drug discovery, the progression of a lead candidate through various…

ADME liabilities identified late during portfolio review – impact on IND success probability

“`html Understanding Late-Identified ADME Liabilities and Their Impact on IND Success In the complex landscape of drug development, late identification of Absorption, Distribution, Metabolism, and Excretion (ADME) liabilities can prove…

Poor hit-to-lead progression before IND-enabling studies – impact on IND success probability

Analyzing Poor Hit-to-Lead Progression Before IND-Enabling Studies and Its Impact on IND Success In the pharmaceutical industry, the successful transition from hit-to-lead compounds to IND-enabling studies is critical for ensuring…

Lead candidate fails downstream criteria before IND-enabling studies – impact on IND success probability

Investigation of Lead Candidate Failure in Downstream Criteria Prior to IND-Enabling Studies In the intricate world of drug discovery, a lead candidate that fails to meet downstream criteria before Investigational…

Off-target toxicity signals during translational assessment – data package strengthening approach

Assessing Off-Target Toxicity Signals in Translational Studies: A Methodical Approach In the pharmaceutical landscape, detecting off-target toxicity signals during the translational assessment phase can significantly influence drug development trajectories. This…

Lead candidate fails downstream criteria during early discovery – impact on IND success probability

Addressing the Challenges When a Lead Candidate Fails Downstream Criteria in Early Discovery In the landscape of pharmaceutical research and drug development, the identification and selection of lead candidates is…

ADME liabilities identified late during regulatory interaction preparation – risk mitigation strategy

Identifying Late-Stage ADME Liabilities in Regulatory Preparations: An Investigative Approach In the dynamic landscape of pharmaceutical research and drug development, encountering ADME (Absorption, Distribution, Metabolism, and Excretion) liabilities late in…

Target validation uncertainty during regulatory interaction preparation – impact on IND success probability

Addressing Target Validation Uncertainty in Regulatory Interaction Preparation to Enhance IND Success Probability Target validation is a critical phase in the drug discovery process, providing evidence that a therapeutic target…